Promising combo for aggressive breast cancer falls short in early trial
NCT ID NCT04216472
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tested a two-drug combination (nab-paclitaxel and alpelisib) given before surgery to people with a hard-to-treat type of breast cancer called triple-negative breast cancer that also had specific genetic changes (PIK3CA or PTEN). The goal was to see if the drugs could shrink or eliminate the tumor before surgery. Only 6 people took part before the study was stopped early, so the results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.